This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in


Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The key agent triggering kinin production is factor XIIa, activated Hageman factor. This converts plasma or tissue prekallikrein, an inactive precursor, into kallikrein. Kallikrein is an enzyme which acts on kininogens, another group of plasma inactive precursor proteins. Kallikrein co-incidentally exhibits chemotactic activity for leukocytes. Kallikreins activate, and kininogens are co-factors in the production of, factor XIIa, so supporting amplification circuits.

Kininogens are cleaved into different kinin products depending on the source of kallikrein or homologous enzyme:

  • tissue kallikreins in exocrine glands such as the pancreas and salivary glands generate a decapeptide termed kallidin
  • plasma kallikrein produces a nonapeptide termed bradykinin
  • mast cells and basophils release a serine protease with similar activity to kallikrein
  • activated complement factor C2 has a kinin-type activity

All the elements forming bradykinin leak out of vessels at the site of inflammation, so localising the response to the site in which factor XII encounters damaged tissue e.g. exposed collagen.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.